BMI1 and mild neurocognitive disorder: Triple immunolabeling for PAX7, BMI1, and EZH2 (Figure S5) revealed an overall decrease of EZH2+ cells in IIM and MND cases (Figure S6A) with a significant decrease of EZH2+ cells in PAX7+ satellite cell (Figure S6B).